A - 78 Characterization of Post-Stroke Cognitive and Mood Impairment within 1-Year Post-Stroke after Hospital Discharge

OBJECTIVE

To demonstrate the feasibility of cognitive and psychological characterization after stroke during post-discharge neurology visit as part of standard care.

METHOD

From January 1, to April 29, 2023, 33 patients were evaluated using the MoCA and screening tests for aphasia, spatial neglect, depression, and anxiety during their neurology outpatient visit. Neuropsychological measures evaluating attention, processing speed, language, visuospatial, memory, and executive function abilities were also administered. Patients were aged 30-87 years (Mage = 64.8, SDage = 14.2). The sample included 37.1% women and was primarily Black/African American (37.1%) and White (54.3%). The average level of education was some college (Medu = 14.7, SDedu = 32.7). Time between stroke and testing ranged from 0-11 months (Melapsed = 2.8, SDelapsed = 3.1 and 88.6% of patients experienced ischemic stroke.

RESULTS

Over 68% of patients examined demonstrated global cognitive impairment on the MoCA (MMoCA = 21.2, SDMoCA = 5.1). 5.7% of patients met criteria for spatial neglect and 5.7% met criteria for aphasia. A higher percentage demonstrated impairments within visuospatial or language domains (51.4% visuospatial and 34.3% language, respectively. Further, impairments were observed across all other domains assessed, including attention (22.9%), processing speed (31.4%), verbal memory (62.9%), visual memory (54.3%), and executive function (51.4%). Depression and anxiety were present in 42.9% and 37.1% of the sample, respectively. Elapsed time, type of stroke, lateralization of stroke, sex, or mood scores were not associated with lower performance on the MoCA.

CONCLUSIONS

Cognitive and behavioral deficits following stroke can be identified as part of standard neurologic care that may otherwise have been missed, providing an opportunity to intervene and maximize recovery in stroke patients.

Telemedicine impact on post-stroke outpatient follow-up in an academic healthcare network during the COVID-19 pandemic

BACKGROUND

The expansion of telemedicine associated with the COVID-19 pandemic has influenced outpatient medical care. The objective of our study was to determine the impact of telemedicine on post-acute stroke clinic follow-up.

METHODS

We retrospectively evaluated the impact of telemedicine in Emory Healthcare, an academic healthcare system of comprehensive and primary stroke centers in Atlanta, Georgia, on post-hospital stroke clinic follow-up. We compared the frequency of 90-day follow-up in a centralized subspecialty stroke clinic among patients hospitalized before the local COVID-19 pandemic (January 1, 2019- February 28, 2020), during (March 1- April 30, 2020) and after telemedicine implementation (May 1- December 31, 2020). A comparison was made across hospitals less than 1 mile, 10 miles, and 25 miles from the stroke clinic.

RESULTS

Of 1096 ischemic stroke patients discharged home or to a rehab facility during the study period, 342 (31%) had follow-up in the Emory Stroke Clinic (comprehensive stroke center 46%, primary stroke center 10 miles away 18%, primary stroke center 25 miles away 14%). Overall, 90-day follow-up increased from 19% to 41% after telemedicine implementation (p<0.001) with telemedicine appointments amounting for up to 28% of all follow-up visits. In multivariable analysis, factors associated with teleneurology follow-up (vs no follow-up) included discharge from the comprehensive stroke center, thrombectomy treatment, private insurance, private transport to the hospital, NIHSS 0-5 and history of dyslipidemia.

CONCLUSIONS

Despite telemedicine implementation at an academic healthcare network successfully increasing post-stroke discharge follow-up in a centralized subspecialty stroke clinic, the majority of patients did not complete 90-day follow-up during the COVID-19 pandemic.

Abstract 13 A Randomized, Placebo-Controlled, Phase II Trial of Intravenous Allogeneic Umbilical Cord Blood Infusion for Adults with Ischemic Stroke

Introduction

Stroke is the fifth leading cause of death in the United States. Tissue plasminogen activator and mechanical thrombectomy are the only effective treatments, but many patients are ineligible for these treatments.

Objective

The objective of this study was to determine whether an intravenous infusion of a non-HLA matched, unrelated donor umbilical cord blood (UCB) would improve functional outcomes.

Methods

We conducted a phase II multicenter, randomized (2:1), placebo controlled, double-blinded trial of UCB in adults with acute ischemic stroke. Patients had to have adequate immune function. Cord blood units were selected from U.S. public cord banks based on blood type, race, and cell dose. Study product was infused 3-10 days post stroke. Participants were randomized within strata of National Institutes of Health Stroke Scale Score (NIHSS) (&lt;12 vs ≥12), and study center. The primary endpoint was change in Modified Rankin Scale (mRS) (baseline minus day 90). The study was powered at 80% (odds ratio of 2). Key secondary outcomes included functional independence at day 90 (mRS &lt;2), NIHSS, the Barthel Index, infusion reactions, and adverse events.

Results

Seventy-nine participants were enrolled at 6 centers when the trial was closed early due to slow accrual related to COVID19; 73 participants (47 randomized to UCB) were included in the safety and efficacy analyses. The median (range) of the change in mRS was 1 (–2, 3) in UCB and 1 (–1, 4) in placebo. A shift analysis based on the proportional odds model showed an odds ratio of 0.9 (95% CI: 0.4, 2.3) after adjustment for baseline mRS and randomization strata. No differences were observed on the key secondary outcomes. There were 17 mild infusion reactions (27.6% UCB; 15.4% placebo). The distribution of serious and non-serious adverse events was similar between arms.

Discussion

This study demonstrated the safety of infusing non-HLA matched UCB to adults with acute ischemic stroke. Feasibility and logistics were challenging. The primary efficacy endpoint did not demonstrate benefit in this underpowered sample size. In a secondary ad hoc analysis, a trend of improved functional outcomes at day 90 in recipients of UCB more than 5 days post stroke (Figure 1) could be explored in future trials.

Clinical Imaging-Derived Metrics of Corticospinal Tract Structural Integrity Are Associated With Post-stroke Motor Outcomes: A Retrospective Study

Objective

The primary objective of this study was to retrospectively investigate associations between clinical magnetic resonance imaging-based (MRI) metrics of corticospinal tract (CST) status and paretic upper extremity (PUE) motor recovery in patients that completed acute inpatient rehabilitation (AR) post-stroke.

Methods

We conducted a longitudinal chart review of patients post-stroke who received care in the Emory University Hospital system during acute hospitalization, AR, and outpatient therapy. We extracted demographic information, stroke characteristics, and longitudinal documentation of post-stroke motor function from institutional electronic medical records. Serial assessments of paretic shoulder abduction and finger extension were estimated (E-SAFE) and an estimated Action Research Arm Test (E-ARAT) score was used to quantify 3-month PUE motor function outcome. Clinically-diagnostic MRI were used to create lesion masks that were spatially normalized and overlaid onto a white matter tract atlas delineating CST contributions emanating from six cortical seed regions to obtain the percentage of CST lesion overlap. Metric associations were investigated with correlation and cluster analyses, Kruskal-Wallis tests, classification and regression tree analysis.

Results

Thirty-four patients met study eligibility criteria. All CST overlap percentages were correlated with E-ARAT however, ventral premotor tract (PMv) overlap was the only tract that remained significantly correlated after multiple comparisons adjustment. Lesion overlap percentage in CST contributions from all seed regions was significantly different between outcome categories. Using MRI metrics alone, dorsal premotor (PMd) and PMv tracts classified recovery outcome category with 79.4% accuracy. When clinical and MRI metrics were combined, AR E-SAFE, patient age, and overall CST lesion overlap classified patients with 88.2% accuracy.

Conclusions

Study findings revealed clinical MRI-derived CST lesion overlap was associated with PUE motor outcome post-stroke and that cortical projections within the CST, particularly those emanating from non-M1 cortical areas, prominently ventral premotor (PMv) and dorsal premotor (PMd) cortices, distinguished between PUE outcome groups. Exploratory predictive models using clinical MRI metrics, either alone or in combination with clinical measures, were able to accurately identify recovery outcome category for the study cohort during both the acute and early subacute phases of post-stroke recovery. Prospective studies are recommended to determine the predictive utility of including clinical imaging-based biomarkers of white matter tract structural integrity in predictive models of post-stroke recovery.

Anticoagulation Therapy Reduces Recurrent Stroke in Embolic Stroke of Undetermined Source Patients With Elevated Coagulation Markers or Severe Left Atrial Enlargement

Background: The objective of this study was to evaluate if anticoagulation therapy reduces recurrent stroke in embolic stroke of undetermined source (ESUS) patients with left atrial enlargement (LAE) or abnormal markers of coagulation and hemostatic activity (MOCHA) compared to antiplatelet therapy.

Methods: ESUS patients from January 1, 2017, to June 30, 2019, underwent outpatient cardiac monitoring and the MOCHA profile (serum d-dimer, prothrombin fragment 1.2, thrombin–antithrombin complex, and fibrin monomer). Anticoagulation was offered to patients with abnormal MOCHA (≥2 elevated markers) or left atrial volume index 40 mL/m². Patients were evaluated for recurrent stroke or major hemorrhage at routine clinical follow-up. We compared this patient cohort (cohort 2) to a historical cohort (cohort 1) who underwent the same protocol but remained on antiplatelet therapy.

Results: Baseline characteristics in cohort 2 (n = 196; mean age = 63 ± 16 years, 59% female, 49% non-White) were similar to cohort 1 (n = 42) except that cohort 2 had less diabetes (43 vs. 24%, p = 0.01) and more tobacco use (26 vs. 43%, p = 0.04). Overall, 45 patients (23%) in cohort 2 initiated anticoagulation based on abnormal MOCHA or LAE. During mean follow-up of 13 ± 10 months, cohort 2 had significantly lower recurrent stroke rates than cohort 1 (14 vs. 3%, p = 0.009) with no major hemorrhages.

Conclusions: Anticoagulation therapy in a subgroup of ESUS patients with abnormal MOCHA or severe LAE may be associated with a reduced rate of recurrent stroke compared to antiplatelet therapy. A prospective, randomized study is warranted to validate these results.

The Utility of the Markers of Coagulation and Hemostatic Activation Profile in the Management of Embolic Strokes of Undetermined Source

BACKGROUND

Potential causes of embolic stroke of undetermined source (ESUS) include occult malignancy, venous thrombosis (VTE) with paradoxical embolism, and hypercoagulable disorders. Given the association of markers of coagulation and hemostatic activation (MOCHA) with these causes, the objective of this study was to validate the utility of the MOCHA profile in identifying the underlying cause of stroke.

METHODS

We prospectively identified ESUS patients from January 1, 2017 to December 1, 2019 who underwent MOCHA profile (plasma d-dimer, prothrombin fragment 1.2, thrombin-antithrombin complex, fibrin monomer) testing. Abnormal MOCHA profile was defined as ≥ 2 abnormal markers. New diagnoses of malignancy, VTE, hypercoagulable disorders and recurrent stroke were identified during routine clinical follow-up.

RESULTS

Of 236 ESUS patients, 104 (44%) patients had an abnormal MOCHA profile. In multivariable analyses the number of MOCHA abnormalities was significantly associated with malignancy, VTE, and hypercoagulable disorders (OR 2.59, CI 95% 1.78-3.76, p<0.001). Sensitivity, specificity, positive predictive value, and negative predictive value of an abnormal MOCHA profile for the combined outcome of malignancy, VTE, and hypercoagulability was 96%, 62%, 23%, and 99% respectively.

DISCUSSION

The MOCHA profile was able to identify ESUS patients more likely to have malignancy, VTE, and hypercoagulable disorders during follow-up. Our results show that a normal MOCHA profile in ESUS patients can effectively rule out these potential causes of ESUS.

Depression in Poststroke Aphasia

Purpose The aim of this tutorial is to provide speech-language pathologists with foundational knowledge of poststroke depression comorbidly occurring with aphasia. Given the negative effect of depression on functional outcomes and mortality, it is crucial that speech-language pathologists possess this knowledge in order to better advocate for and treat their patients. Method and Results Three areas of complementary expertise (speech-language pathology, psychology, and neurology) collaborated on this tutorial to address the following areas: (a) provide terminology associated with depression and related mood disorders, (b) describe the potential underlying pathophysiology of depression in the general population, (c) provide an overview of our existing understanding of comorbid poststroke depression and aphasia, and (d) summarize current assessment methods and interventions for poststroke depression in adults with aphasia. Conclusion Given the compounding impact aphasia and depression have on rehabilitation outcomes, it is imperative that speech-language pathologists understand terminology, assessment, and treatment practices for depression.

Markers of coagulation and hemostatic activation aid in identifying causes of cryptogenic stroke

OBJECTIVE

To test the hypothesis that markers of coagulation and hemostatic activation (MOCHA) help identify causes of cryptogenic stroke, we obtained serum measurements on 132 patients and followed them up to identify causes of stroke.

METHODS

Consecutive patients with cryptogenic stroke who met embolic stroke of undetermined source (ESUS) criteria from January 1, 2017, to October 31, 2018, underwent outpatient cardiac monitoring and the MOCHA profile (serum D-dimer, prothrombin fragment 1.2, thrombin-antithrombin complex, and fibrin monomer) obtained ≥2 weeks after the index stroke; abnormal MOCHA profile was defined as ≥2 elevated markers. Prespecified endpoints monitored during routine clinical visits included new atrial fibrillation (AF), malignancy, venous thromboembolism (VTE), or other defined hypercoagulable states (HS).

RESULTS

Overall, 132 patients with ESUS (mean age 64 ± 15 years, 61% female, 51% nonwhite) met study criteria. During a median follow-up of 10 (interquartile range 7-14) months, AF, malignancy, VTE, or HS was identified in 31 (23%) patients; the 53 (40%) patients with ESUS with abnormal MOCHA were significantly more likely than patients with normal levels to have subsequent new diagnoses of malignancy (21% vs 0%, p < 0.001), VTE (9% vs 0%, p = 0.009), or HS (11% vs 0%, p = 0.004) but not AF (8% vs 9%, p = 0.79). The combination of 4 normal MOCHA and normal left atrial size (n = 30) had 100% sensitivity for ruling out the prespecified endpoints.

CONCLUSION

The MOCHA profile identified patients with cryptogenic stroke more likely to have new malignancy, VTE, or HS during short-term follow-up and may be useful in direct evaluation for underlying causes of cryptogenic stroke.

Abstract WP264: Frequency of Hypercoagulability in Patients With Embolic Stroke of Undetermined Source and Patent Foramen Ovale

Introduction: Patent foramen ovale (PFO) is more commonly found in patients with cryptogenic stroke and paradoxical embolism is commonly assumed to be the primary mechanism. Our objective was to determine the frequency of hypercoagulability in cryptogenic stroke patients and PFO.

Methods: Consecutive patients with embolic stroke of undetermined source (ESUS) seen at the Emory Clinic from January 1, 2017 to June 30, 2019 who underwent echocardiogram with bubble study and markers of coagulation and hemostatic activation (MOCHA) testing (serum d-dimer, prothrombin fragment 1.2, thrombin-antithrombin complex, fibrin monomer) were included; abnormal MOCHA was defined as ≥ 2 elevated markers. Venous thromboembolism, malignancy, other defined hypercoagulable state, and the composite outcome were assessed at routine follow-up and compared across groups based on PFO status.

Results: Of 172 patients (mean age 63 ± 16 years, 60% female), 40 (23%) had a PFO. Compared to the PFO- group, the PFO+ group was younger (p=<0.001), less likely to have hypertension (p<0.001) and diabetes (p=0.011), and had a higher ROPE score (p=0.007) (Table 1). There was no difference in the frequency of abnormal MOCHA between groups and the composite outcome was less frequent in PFO+ versus PFO- patients (p=0.017). In the subgroup of patients <60 years old, there was no difference in the frequency of abnormal MOCHA and the composite outcome.

Conclusion: Hypercoagulability as measured by MOCHA was not associated with the presence of PFO in ESUS patients. Based on our results, ESUS patients should undergo a detailed evaluation for alternative causes of stroke other than paradoxical embolism.

Abstract TP90: Advance: Automated Detection and Volumetric Assessment of Intracerebral Hemorrhage

Introduction: Intracerebral hemorrhages (ICHs) accounts for approximately 15% of all strokes but carry high rates of morbidity and mortality. The location and volume of hematoma are strongly associated with outcomes. As novel treatments become established, early detection and proper volume measurement are becoming increasingly important. We aim to evaluate an artificial intelligence-based algorithm (Viz-ICH® v1.4) for ICH detection, volume measurement, and its differentiation from intraventricular hemorrhage (IVH).

Methods: We performed single center retrospective analysis of non-contrast CTs (NCCTs), randomly picked from prospective cohort of acute stroke patients, with and without parenchymal ICHs, admitted to our stroke center from 02/14-03/17. Experienced stroke neurologists graded NCCTs with a semi-automated tool (OsiriX MD v.9.0.1) for presence and volume of ICH, and also presence of intraventricular hemorrhage (IVH). AI- and human-based readings were compared.

Results: A total of 211 NCCTs were evaluated including 163 ICHs and 48 controls. The ICH location was basal ganglionic in 55.8%, Lobar in 23.3% and posterior fossa in 12% of the cases and 51.5 % of patients had associated IVH with mean volume 41.94 cc. The AI algorithm demonstrated high accuracy for ICH detection and volumetric measurement (Table). The maximal running time of the algorithm was under 15s.

Conclusion: The presence and volume of ICHs can be accurately detected by AI Viz-ICH Algorithm, with good differentiation from IVH which will help in early triage of these patients.

Abstract WMP118: Anticoagulation Therapy Reduces Recurrent Stroke in Embolic Stroke of Undetermined Source (ESUS) Patients With Elevated Coagulation Markers or Severe Left Atrial Enlargement

Introduction: Left atrial enlargement (LAE) and markers of coagulation and hemostatic activation (MOCHA) have previously been shown to identify ESUS patients who are more likely to have subsequent diagnosis of atrial fibrillation (AF), malignancy or recurrent strokes. The objective of this study was to evaluate if anticoagulation therapy reduces recurrent stroke in ESUS patients with LAE or abnormal MOCHA.

Methods: Consecutive ESUS patients seen in the Emory Clinic from January 1, 2017, to June 30, 2019, underwent outpatient cardiac monitoring and the MOCHA profile (serum d-dimer, prothrombin fragment 1.2, thrombin-antithrombin complex and fibrin monomer) obtained ≥ 2 weeks after the index stroke. All patients were on antiplatelet therapy at the time of testing. Anticoagulation was offered to patients with an abnormal MOCHA (≥ 2 elevated markers) or severe LAE (LA volume index >40 ml/m 2 ). Patients were evaluated for AF, malignancy, recurrent stroke or hemorrhage at routine clinical follow-up. We compared this patient cohort (cohort 2) to a historical cohort (cohort 1) who underwent the same protocol but remained on antiplatelet therapy during follow-up.

Results: Baseline characteristics and endpoints are shown in the Table. Overall 46 (23%) patients in Cohort 2 initiated anticoagulation based on abnormal MOCHA or severe LAE. Cohort 2 had significantly lower rates of recurrent stroke than cohort 1 (14% vs. 3%, p=0.008) with no major hemorrhages.

Conclusion: Anticoagulation therapy in a subgroup of ESUS patients with abnormal MOCHA or severe LAE may be associated with a reduced rate of recurrent stroke. A prospective, multicenter study is warranted to validate these results.

Abstract WP351: Strokophobia Among Neurology, Internal Medicine and Emergency Medicine Residents

Clinical care of acute stroke patients can be handled by multiple specialties yet the concept of “strokophobia”, or the fear of dealing with stroke patients has not been explored in the literature. We explore some of the roots of that fear in residents of the neurology, emergency medicine (EM) and internal medicine (IM) specialties. An anonymous survey was sent to neurology, IM and EM residents at two different academic institutions. The survey inquired about the respondent’s demographics, training, and the first time the had a strong discomfort dealing with stroke. More detailed questions followed regarding some of the common perceived misconceptions and reasons behind the fear of caring for stroke patients. The questionnaire also inquired about some available resources to mitigate that fear. Of the 47 respondents, 47% were male. 57% were in IM, 38% were in neurology, and 4% from EM. 23% were in their PGY1 of training, 30 % were PGY2, 32% PGY3, and 15% PGY4. Most residents (83%) had an inpatient component in their neurology clerkship. 66% report having some fear in dealing with stroke patients. 28% report the fear to originally stem from the clinical years of medical school and 28% during residency. 40% of residents agreed that more neuroanatomy teaching is needed and 36% did not think enough education was given in medical school. 11% did not have a neurology clerkship in their medical school, 4% did not have an opportunity to work with a neurologist in medical school. 25% of residents report having limited exposure to stroke patients. 23% of residents consult neurology out of fear of missing significant pathology, while 23% were not comfortable with their exam skills. 38 % residents blame excessive paperwork for the lack of education while 23% think it was witnessing some attendings uncomfortable with stroke patients. The high acuity of these patients would deter 30% of the residents from caring for them. 11% of residents shy away due to having to establish adequate time windows or asking for help. 72% agree that more hands-on teaching is needed while 38% state that more tutorial videos could be helpful. In this first-ever exploratory analysis of strokophobia, the results show that the phenomenon is prevalent and more education is needed in order to mitigate it amongst residents.

Abstract 27: Biomarkers of Coagulation and Hemostatic Activation in the Post-Acute Period Effectively Rule Out Hypercoagulable States in Patients With Embolic Stroke of Undetermined Source

Introduction: We previously reported that markers of coagulation and hemostatic activation (MOCHA) have been associated with malignancy, venous thromboembolism (VTE) and hypercoagulable states in embolic stroke of undetermined source (ESUS) patients. The objective of our study was to identify independent predictors of these endpoints.

Methods: Consecutive ESUS patients seen at the Emory Clinic from January 1, 2017 to June 30, 2019 underwent a MOCHA profile (d-dimer, prothrombin fragment 1.2, thrombin-antithrombin complex, fibrin monomer) and were followed prospectively for new diagnoses of malignancy, VTE, other defined hypercoagulable states and the composite outcome. Abnormal MOCHA was defined as ≥ 2 elevated markers. Multivariable analyses were performed to identify predictors of the composite outcome.

Results: Of 188 patients (mean age 63 ±16 years, 59% female, 50% Caucasian) included in the study period, 25 (13%) had the composite outcome. The median time between ESUS to MOCHA testing was 45 days (IQR 23-88). Abnormal MOCHA profile was the only independent predictor of the composite outcome (OR 2.34, 1.64-3.32, p<0.001) (AUC 0.824); age, sex, race, any history of tobacco use, hypertension, diabetes, history of stroke, cortical stroke, migraine, and left atrial size were not predictive. Abnormal MOCHA had a 96% sensitivity, 32% positive predictive value and 99% negative predictive value for the composite outcome.

Conclusions: This study confirms that a normal MOCHA profile in the post-acute time period can rule out ESUS patients with malignancy, VTE or other underlying hypercoagulable states.

Abstract WP61: Artificial Intelligence for Automated Detection of Large Vessel Occlusion Strokes

Introduction: Identification of Large Vessel Occlusion (LVO) in acute ischemic stroke (AIS) patients is critical for proper decision-making. Limited availability of trained experts and delays in LVO recognition can have a detrimental effect on outcomes. We sought to evaluate an artificial intelligence-based algorithm for LVO detection in AIS.

Methods: A retrospective analysis of a prospectively-collected database of AIS patients admitted to a large volume stroke center between 2014-2018 was performed. Experienced vascular neurologists graded CTA for presence and site of LVO. Concurrently, studies were analyzed by the Viz-LVO Algorithm® version 1.4 (GA) - a convolutional neural network programmed to detect occlusions from the internal carotid artery terminus (ICA-T) to the sylvian fissure, which would include all MCA M1-segment and most M2-segment lesions. CTA readings were categorized as LVOs (ICA-T, MCA-M1, MCA-M2) versus non-LVOs/more distal occlusions. Comparisons between human and AI-based readings were done by accuracy analysis and calculating Cohen’s kappa.

Results: A total of 610 CTAs were analyzed. The AI algorithm rejected 3.4% of the CTAs due to poor quality. Viz-LVO identified LVOs with an overall sensitivity of 81.3%, specificity of 87.8%, and accuracy of 83.2% (AUC 0.845 (95%CI:0.81-0.88, p<0.001). Table 1 shows the results per occlusion site. Accuracy was higher for ICA-T and M1 occlusions as compared to M2 occlusions. The mean run time of the algorithm was 2.78±0.5minutes.

Conclusion: Our study demonstrates that automated AI reading allows for fast and accurate identification of LVO strokes. Future efforts should be made to improve the detection of the more distal occlusions.

Abstract WP529: Anticoagulation Therapy Reduces Recurrent Stroke in Embolic Stroke of Undetermined Source (ESUS) Patients With Elevated Markers of Coagulation and Hemostatic Activation

Introduction: Markers of coagulation and hemostatic activation (MOCHA) have previously been shown to identify ESUS patients who are more likely to have subsequent diagnosis of atrial fibrillation (AF), malignancy, venous thromboembolism (VTE) or other defined hypercoagulable disorders. The objective of this study was to evaluate whether anticoagulation therapy reduces recurrent stroke in ESUS patients with an abnormal MOCHA profile.

Methods: Consecutive ESUS patients seen in the Emory Clinic from January 1, 2017 to June 30, 2018 underwent outpatient cardiac monitoring and the MOCHA profile including serum d-dimer, prothrombin fragment 1.2, thrombin-antithrombin complex and fibrin monomer obtained ≥ 2 weeks after the index stroke. All patients were on antiplatelet therapy at the time of MOCHA testing and an abnormal MOCHA profile was defined as ≥ 2 elevated markers. Anticoagulation was offered to patients with an abnormal MOCHA and patients were evaluated for recurrent stroke or hemorrhage at routine clinical follow-up. We compared this patient cohort (cohort 2) to a historical cohort (cohort 1) who underwent the same protocol but remained on antiplatelet therapy during follow-up.

Results: Baseline characteristics were similar between cohorts except that cohort 2 was less likely to have diabetes (43% vs 23%, p=0.004), less likely to have an abnormal MOCHA profile (55% vs 36%, p=0.008) and had a shorter duration of follow-up (mean months 13 vs 7, p=0.0001). Cohorts had similar rates of the composite endpoint of AF, malignancy, VTE or other defined hypercoagulable disorder (33% vs 26%, p=0.43). MOCHA profile was obtained a median of 33 (IQR 15-57) days after index stroke in cohort 2; 41 (36%) patients were offered the option of anticoagulation therapy due to an abnormal MOCHA profile of which 32 (78%) chose anticoagulation. Cohort 2 had significantly lower rates of recurrent stroke than cohort 1 (14% vs. 0.9%, IRR 0.14, p=0.01) with no major hemorrhages seen in either group.

Conclusion: This study suggests that anticoagulation therapy in a subgroup of ESUS patients with abnormal MOCHA profile may be associated with a reduced rate of recurrent stroke. A prospective, randomized study is needed to confirm these findings.

Abstract 122: Markers of Coagulation and Hemostatic Activation Identify Embolic Stroke of Undetermined Source (ESUS) Patients who are at Risk of Recurrent Thrombotic Events on Antiplatelet Therapy: A Validation Study

Introduction: Markers of coagulation and hemostatic activation (MOCHA) have previously been shown to identify ESUS patients who are more likely to have subsequent diagnosis of atrial fibrillation (AF) or malignancy. The objective of this study was to validate these results in a larger ESUS cohort.

Methods: Consecutive ESUS patients seen in the Emory Clinic from January 1, 2017 to June 30, 2018 underwent outpatient cardiac monitoring and the MOCHA profile including serum d-dimer, prothrombin fragment 1.2, thrombin-antithrombin complex and fibrin monomer obtained ≥ 2 weeks after the index stroke. All patients were on antiplatelet therapy at the time of MOCHA testing and an abnormal MOCHA profile was defined as ≥ 2 elevated markers. Prespecified endpoints monitored during routine clinical follow-up included diagnosis of AF, malignancy, venous thromboembolism (VTE) or other defined hypercoagulable states.

Results: During the study period, 113 ESUS patients (mean age 64 +/- 15 years, 63% female, 54% non-white) underwent prolonged cardiac monitoring (70% MCOT, 42% ILR) and MOCHA profile testing (median days from stroke 33, IQR 15-57). During a mean follow-up of 7 ± 4 months, AF, malignancy, VTE or other defined hypercoagulable state was identified in 30 (27%) patients; the 41 (36%) ESUS patients with an abnormal MOCHA profile were significantly more likely to have an endpoint than patients with a normal profile (59% vs 8%, p<0.0001). The absence of any elevated MOCHA tests (n=41) had 100% sensitivity for the prespecified endpoints.

Conclusion: In this validation study, we found that the MOCHA profile identified ESUS patients more likely to have AF, malignancy, VTE or other defined hypercoagulable states during follow-up and may identify a subgroup of ESUS patients who could benefit from early anticoagulation; a normal MOCHA profile identifies ESUS patients who have a low risk of developing these endpoints on antiplatelet therapy.

Abstract WP278: Markers of Coagulation and Hemostatic Activation in Embolic Stroke of Undetermined Source (ESUS) Patients With Patent Foramen Ovale

Introduction: Recent randomized trials have shown that patent foramen ovale (PFO) closure combined with antiplatelet therapy in cryptogenic stroke patients ≤ 60 years of age is associated with a reduced risk of stroke compared to antiplatelet therapy alone, presumably by preventing a paradoxical embolism. The objective of this study was to evaluate the MOCHA profile, a sensitive marker of venous thromboembolism (VTE), in ESUS patients with PFO.

Methods: Consecutive ESUS patients ≥ 18 years of age seen in the Emory Clinic from January 1, 2017 to June 30, 2018 underwent testing of MOCHA including serum d-dimer (DD), prothrombin fragment 1.2 (PTF1.2), thrombin-antithrombin (TAT) complex and fibrin monomer (FM). All patients were on antiplatelet therapy at the time of MOCHA testing and an abnormal MOCHA profile was defined as ≥ 2 elevated markers. We compared baseline characteristics and clinical outcomes between patients with and without PFO.

Results: During the study period, 113 ESUS patients (mean age 64 +/- 15 years, 63% female, 54% non-white, 20% PFO) underwent MOCHA profile testing; 37 (32.7%) were ≤ 60 years of age. In the subgroup ≤ 60 years of age, the 11 (23%) PFO+ patients were younger (mean age 40 vs 46, p=0.009), more likely to be white (55% vs 35%, p=0.0001) and had higher ROPE score (median 8 vs 6, p=0.06) than PFO- patients. There was no significant difference between PFO+ and PFO- patients in the frequency of abnormal MOCHA (18% vs 19%), mean DD, PTF1.2, TAT, FM and frequency of VTE (1 event in each group). PFO+ and PFO- patients had a high frequency of migraine with aura (64%, 38%, p=0.15) and headache days in the month prior to stroke (mean 11 vs 5, p=0.72). In multivariable analysis of the overall cohort, age (OR 1.14 1.06-1.22 p<0.001) and ROPE score (OR 2.29 1.13-4.65 p=0.02) were significantly associated with abnormal MOCHA while PFO status (p=0.4) and migraine (p=0.23) were not.

Conclusion: In ESUS patients ≤ 60 years of age, there was no difference in the MOCHA profile between PFO+ and PFO- patients. The high frequency of migraine with aura and headache days in the month prior to stroke regardless of PFO status needs further study to evaluate its role in young ESUS patients.

Abstract TMP7: Not All mTICI 2b Are Made Equal: Balancing the Risks and Benefits of the Ideal Reperfusion Target in Endovascular Stroke Therapy

Introduction: The standard reperfusion target for thrombectomy trials has been modified TICI (mTICI) 2b-3 (≥50% ischemic territory). Recently, full reperfusion (mTICI 2c-3) has been recommended as the ideal target. The potential added benefits of additional procedural maneuvers must be balanced against their risks, particularly when dealing with residual distal occlusions often found in mTICI 2b. It remains unknown whether more precise categorization of the mTICI2b strata leads to more reasonable treatment targets.

Methods: Retrospective analysis of prospectively collected thrombectomy data spanning Jun 2011-Feb 2018. Inclusion criteria: MCA and intracranial internal carotid artery occlusions. Definitions of reperfusion: mTICI0-1: no or limiteddistal filling; mTICI2a: <50% of territory; mTICI2b-: 50-74% of territory; mTICI2b+: 75-99%; mTICI3: full.

Results: Of 557 patients, 2.2% had mTICI0-1, 3.6% had mTICI2a, 5.9% had mTICI2b-, 30.2% mTICI2b+, and 58.2% mTICI3. The usage of intravenous tPA was lower in the mTICI2b- vs. mTICI3 (18% vs. 41%;p<0.01) patients but otherwise there were no differences in baseline characteristics (age, gender, hypertension, diabetes, atrial fibrillation, NIHSS, occlusion site). Parenchymal hematomas were comparable between groups. The rates of good outcome (90-day mRS0-2) were comparable between mTICI3 vs mTICI2b+ (52% vs 46%;p=0.2) but were significantly lower in the mTICI2b- (30%;p=0.02), mTICI2a (5%; p<0.001) and mTICI0-1 (9%;p=0.003) groups (mTICI 3 as reference) ( Figure ). Mortality rates were comparable across the mTICI2b-, mTICI 2b+, and mTICI 3 groups but higher with mTICI2a (40%;p=0.01) and mTICI0-1 (50%;p<0.01) vs mTICI3 (16%).

Conclusion: There is broad variation in outcomes across the different degrees of reperfusion within the mTICI 2b grade. A reperfusion target of 75%-99% (mTICI2b+) may lead comparable rates of independence versus full reperfusion.

Coagulation markers and echocardiography predict atrial fibrillation, malignancy or recurrent stroke after cryptogenic stroke

We evaluated the utility of left atrial volume index (LAVI) and markers of coagulation and hemostatic activation (MOCHA) in cryptogenic stroke (CS) patients to identify those more likely to have subsequent diagnosis of atrial fibrillation (AF), malignancy or recurrent stroke during follow-up.Consecutive CS patients who met embolic stroke of undetermined source (ESUS) who underwent transthoracic echocardiography and outpatient cardiac monitoring following stroke were identified from the Emory cardiac registry. In a subset of consecutive patients, d-dimer, prothrombin fragment 1.2, thrombin-antithrombin complex and fibrin monomer (MOCHA panel) were obtained ≥2 weeks post-stroke and repeated ≥4 weeks later if abnormal; abnormal MOCHA panel was defined as ≥2 elevated markers which did not normalize when repeated. We assessed the predictive abilities of LAVI and the MOCHA panel to identify patients with subsequent diagnosis of AF, malignancy, recurrent stroke or the composite outcome during follow-up.Of 94 CS patients (mean age 64 ± 15 years, 54% female, 63% non-white, mean follow-up 1.4 ± 0.8 years) who underwent prolonged cardiac monitoring, 15 (16%) had new AF. Severe LA enlargement (vs normal) was associated with AF (P < .06). In 42 CS patients with MOCHA panel testing (mean follow-up 1.1 ± 0.6 years), 14 (33%) had the composite outcome and all had abnormal MOCHA. ROC analysis showed LAVI and abnormal MOCHA together outperformed either test alone with good predictive ability for the composite outcome (AUC 0.84).We report the novel use of the MOCHA panel in CS patients to identify a subgroup of patients more likely to have occult AF, occult malignancy or recurrent stroke during follow-up. A normal MOCHA panel identified a subgroup of CS patients at low risk for recurrent stroke on antiplatelet therapy. Further study is warranted to evaluate whether the combination of an elevated LAVI and abnormal MOCHA panel identifies a subgroup of CS patients who may benefit from early anticoagulation for secondary stroke prevention.

Abstract 120: Measures of Coagulation and Hemostatic Activation Outperform Left Atrial Structural Parameters in Identifying Embolic Stroke of Undetermined Source (ESUS) Patients Who May Benefit From Early Anticoagulation

Introduction: The objective of this study was to evaluate left atrial (LA) echocardiographic parameters and a novel panel of serum biomarkers to identify ESUS patients who may benefit from early anticoagulation.

Methods: We prospectively identified ESUS patients seen in the Emory Clinic from January 1, 2015 to June 30, 2017 who underwent prolonged cardiac monitoring with mobile cardiac outpatient telemetry (MCOT) and/or implantable loop recorder (ILR). In a subset of consecutive patients, 4 measures of coagulation and hemostatic activation (MOCHA) including d-dimer, prothrombin fragment 1.2, thrombin-antithrombin complex and fibrin monomer were obtained ≥ 2 weeks after the index stroke and repeated if abnormal. We evaluated the ability of LA structural parameters to identify patients with atrial fibrillation (AF) on monitoring and the ability of abnormal MOCHA levels to identify patients who had the composite outcome of newly diagnosed AF, malignancy, or recurrent stroke.

Results: During the study period, 92 ESUS patients (mean age 64 +/- 15 years, 54% female, 62% non-white, mean follow-up 1.4 +/- 0.8 years) underwent prolonged cardiac monitoring (65% MCOT, 62% ILR, 38% MCOT+ILR); 16 (17%) were found to have AF. Severe LA enlargement (vs normal) was associated with subsequent detection of AF (p=0.09) however LA diameter and LA volume index were not. Baseline characteristics of ESUS patients who underwent MOCHA testing (n=44) were similar to patients who did not except that those tested were younger (60 vs 67 years, p=0.04); over mean follow-up of 1.2 +/- 0.8 years, 18 (41%) patients had newly diagnosed AF, malignancy or recurrent stroke. ESUS patients with persistently abnormal (vs normal) MOCHA levels were significantly more likely to have newly diagnosed AF, malignancy or recurrent stroke (OR 11.3, 95% CI 2.5-50.1, p=0.001); elevated levels of ≥ 3 MOCHA markers had a 67% sensitivity and 81% specificity for identifying patients with the composite outcome.

Conclusion: Abnormal MOCHA levels identified ESUS patients who were more likely to have newly diagnosed AF, malignancy or recurrent stroke over follow-up and may be more effective than LA structural abnormalities in identifying patients who could benefit from early anticoagulation.

Clinical and Imaging Outcomes of Endovascular Therapy in Patients with Acute Large Vessel Occlusion Stroke and Mild Clinical Symptoms

Background

The minimal stroke severity justifying endovascular intervention remains elusive. However, a significant proportion of patients presenting with large vessel occlusion stroke (LVOS) and mild symptoms go untreated and face poor outcomes. We aimed to evaluate the clinical outcomes of patients presenting with LVOS and low symptom scores (National Institutes of Health Stroke Scale [NIHSS] score ≤8) undergoing endovascular therapy (ET).

Methods

We performed a retrospective analysis of a prospectively collected ET database between September 2010 and March 2016. Endovascularly treated patients with LVOS and a baseline NIHSS score ≤8 were included. Baseline patient characteristics, procedural details, and outcome parameters were collected. Efficacy outcomes were the rate of good outcome (90-day modified Rankin Scale score 0-2) and of successful reperfusion (modified Treatment in Cerebral Infarction [mTICI] score 2b-3). Safety was assessed by the rate of parenchymal hematoma (parenchymal hematoma type 1 [PH-1] and parenchymal hematoma type 2 [PH-2]) and 90-day mortality. Logistic regression was used to identify predictors of good clinical outcomes.

Results

A total of 935 patients were considered; 72 patients with an NIHSS score ≤8 were included. Median [IQR] age was 61.5 years [56.2-73.0]; 39 patients (54%) were men. Mean (SD) baseline NIHSS score, computed tomography perfusion core volume, and ASPECTS were 6.3 (1.5), 7.5 mL (16.1), and 8.5 (1.3), respectively. Twenty-eight patients (39%) received intravenous tissue plasminogen activator. Occlusions locations were as follows: 29 (40%) proximal MCA-M1, 20 (28%) MCA-M2, 6 (8%) ICA terminus, and 9 (13%) vertebrobasilar. Tandem occlusion was documented in 7 patients (10%). Sixty-seven patients (93%) achieved successful reperfusion (mTICI score 2b-3); 52 (72%) had good 90-day outcomes. Mean final infarct volume was 32.2 ± 59.9 mL. Parenchymal hematoma occurred in 4 patients (6%). Ninety-day mortality was 10% (n = 7). Logistic regression showed that only successful reperfusion (OR 27.7, 95% CI 1.1-655.5, p = 0.04) was an independent predictor of good outcomes.

Conclusion

Our findings demonstrate that ET is safe and feasible for LVOS patients presenting with mild clinical syndromes. Future controlled studies are warranted.

The efficacy of tracheostomy tube changes by speech-language pathologists: A retrospective review

Background/Aims:

The number of tracheostomised patients in the acute care setting are increasing, resulting in an equal need of providers who can safely change tracheostomy tubes without complications. The objective of this retrospective study was to ascertain if trained speech-language pathologists were able to safely and efficiently perform tracheostomy tube changes in the acute care setting with minimal adverse events.

Methods:

Our retrospective case series spans from June 2010 to March 2015 and was completed at an academic hospital with a level 1 trauma designation. A total of 107 consecutive referrals undergoing a tracheostomy tube change, with a speech-language pathologist, were identified. Success was defined as the placement of the tracheostomy tube into the tracheal lumen with confirmation of placement. Only complications occurring at the time of the tracheostomy tube change were considered and were defined as an airway loss event: oxygen desaturation <85%; uncontrollable bleeding >5mL; and the inability to perform the attempted tracheostomy tube change for any other reason.

Results:

All of the tracheostomy tubes changes were performed at the bedside at a mean of 13 days post tracheotomy (range 3–28). A total of 106 (99%) of 107 tracheostomy tubes changes were successfully completed without complications; 83 (79%) of the tracheostomy tubes changes performed were the initial tracheostomy tubes change completed post tracheotomy. The remaining 23 (21%) were a combination of either the second or third change. One, (less than 1%), of the procedures was attempted and discontinued before the removal of the tracheostomy tubes, and referred back to the surgical services and was successfully managed with no untoward effects to the patient.

Conclusions:

This is the first study to audit the outcome of speech-language pathologists' ability to successfully change a tracheostomy tube. The findings suggest that specially trained speech-language pathologists, acting as part of a multi-disciplinary care team, have the potential to safely change tracheostomy tubes in an acute care setting with the availability of immediate physician and respiratory therapy support. Additional clinical benefits of the speech-language pathologist changing tracheostomy tubes may include earlier facilitation of communication, decannulation and initiation of nutrition/hydration.

Carotid Web (Intimal Fibromuscular Dysplasia) Has High Stroke Recurrence Risk and Is Amenable to Stenting

BACKGROUND AND PURPOSE

Carotid webs have been increasingly recognized as a cause of recurrent stroke, but evidence remains scarce. We aim to report the clinical outcomes and first series of carotid stenting in a cohort of patients with strokes from symptomatic carotid webs.

METHODS

Prospective and consecutive data of patients <65 years old with cryptogenic stroke admitted within September 2014 to May 2017. Carotid web was defined by a shelf-like/linear filling defect in the posterior internal carotid artery bulb by computed tomographic angiography.

RESULTS

Twenty-four patients were identified (91.6% strokes/8.4% transient ischemic attacks [TIAs]). Median age was 46 (41-59) years, 61% were female, and 75% were black. Median National Institutes of Health Stroke Scale score was 10.5 (3.0-16.0) and ASPECTS (Alberta Stroke Program Early CT Score) was 8 (7-8). There were no parenchymal hemorrhages, and 96% of patients were independent at 3 months. All webs caused <50% stenosis. In patients with bilateral webs (58%), median ipsilateral web length was larger than contralateral (3.1 [3.0-4.5] mm versus 2.6 [1.85-2.9] mm; P=0.01), respectively. Twenty-nine percent of patients had thrombus superimposed on the symptomatic carotid web. A recurrent stroke/TIA involving the territory of the previously symptomatic web occurred in 7 (32%; 6 strokes/1 TIA) patients: 3 <1 week, 2 <first year, and 3 >1 year of follow-up. Two recurrences occurred on dual antiplatelet therapy, 3 on antiplatelet monotherapy, 1 within 24 hours of thrombolysis, and 1 off antithrombotics. Median follow-up was 12.2 (8.0-18.0) months. Sixteen (66%) patients were stented at a median 12.2 (7.0-18.7) days after stroke with no periprocedural complications. No recurrent strokes/TIAs occurred in stented individuals (median follow-up of 4 [2.4-12.0] months).

CONCLUSIONS

Carotid web is associated with high recurrent stroke/TIA risk, despite antithrombotic use, and is amenable to carotid stenting.

Atrial Fibrillation Predictors on Mobile Cardiac Telemetry in Cryptogenic Ischemic Stroke

Background and Purpose

The objective of our study was to evaluate magnetic resonance imaging (MRI) and echocardiographic characteristics that would identify patients with cryptogenic ischemic stroke (IS) and transient ischemic attack (TIA) who subsequently developed paroxysmal atrial fibrillation (PAF) on mobile cardiac outpatient telemetry (MCOT).

Methods

All patients with cryptogenic IS or TIA seen at the Emory University Hospital and Emory University Hospital Midtown from January 1, 2009, to June 30, 2013, who underwent MCOT were included in this analysis. Location (cortical, high subcortical, or neither) of current and prior strokes on MRI and left atrial (LA) functional and anatomical echocardiographic parameters were evaluated to determine their association with subsequent detection of PAF.

Results

Of 132 patients, 17 (13%) had evidence of newly diagnosed PAF on MCOT (mean duration of monitoring = 25 days). The presence (vs absence) of ≥1 cortical infarct on baseline MRI was a significant predictor of identifying PAF (odds ratio: 5.2, 95% confidence interval: 1.3-19; P = .01). On baseline echocardiography, patients who had PAF (vs non-PAF) had significantly higher mean LA diameters (4.2 vs 3.7 cm, P = .03) and lower tissue Doppler velocity (a'; 5.5 vs 13.5 cm/s, P = .03). In receiver operating characteristic analysis, the ratio of LA volume index to the septal Doppler velocity (LAVI/a') of >4.6 was associated with a higher likelihood of PAF. Combining MRI with echocardiographic variables did not improve the predictive ability beyond echocardiography alone.

Conclusion

Although the presence of cortical-based infarcts on MRI in patients with cryptogenic IS or TIA increases the likelihood of detecting PAF on MCOT, LA functional and anatomic parameters alone best predicted which patients subsequently had PAF.

Tongue-controlled robotic rehabilitation: A feasibility study in people with stroke

Stroke survivors with severe upper limb (UL) impairment face years of therapy to recover function. Robot-assisted therapy (RT) is increasingly used in the field for goal-oriented rehabilitation as a means to improve function in ULs. To be used effectively for wrist and hand therapy, the current RT systems require the patient to have a minimal active range of movement in the UL, and those that do not have active voluntary movement cannot use these systems. We have overcome this limitation by harnessing tongue motion to allow patients to control a robot using synchronous tongue and hand movement. This novel RT device combines a commercially available UL exoskeleton, the Hand Mentor, and our custom-designed Tongue Drive System as its controller. We conducted a proof-of-concept study on six nondisabled participants to evaluate the system usability and a case series on three participants with movement limitations from poststroke hemiparesis. Data from two stroke survivors indicate that for patients with chronic, moderate UL impairment following stroke, a 15-session training regimen resulted in modest decreases in impairment, with functional improvement and improved quality of life. The improvement met the standard of minimal clinically important difference for activities of daily living, mobility, and strength assessments.

Abstract 80: Left Atrial Structural and Functional Parameters in Ischemic Stroke Patients Show Differences in Cardioembolic versus Embolic Strokes of Unknown Source (ESUS) and Other Determined Causes: Rethinking Whether ESUS Patients Should be Treated as Cardioembolic Equivalents

Background: The role of anticoagulation in patients with embolic strokes of unknown source (ESUS) remains controversial. Left atrial (LA) structural and functional parameters on transthoracic echocardiography (TTE) may predict ESUS patients who are likely to develop subsequent paroxysmal atrial fibrillation (PAF).

Hypothesis: LA parameters in ESUS patients will be similar to cardioembolic (CE) stroke patients and different from patients with strokes due to other determined cause (ODC).

Methods: Patients admitted to a stroke center from June 1 to November 30, 2015 with acute ischemic stroke were included in this analysis. Baseline characteristics and results of inpatient diagnostic workup including neuroimaging, echocardiography, and cardiac telemetry were reviewed retrospectively to classify patients into three subtypes: CE, ODC or ESUS. LA diameter, LA volume index (LAVI), mitral valve early (MV E) and late filling peak (MV Peak A) velocities were compared between the 3 subtypes.

Results: Of 131 patients (mean age 67 ± 16, 47% female, 45% white), 35 (27%) were classified as CE, 62 (47%) ODC and 34 (26%) ESUS. Baseline characteristics were similar between groups except that ODC patients were less likely to be female than CE and ESUS patients (p=0.05). LAVI, MV E and MV Peak A were all significantly different in CE compared with ODC and ESUS patients (p<0.05), with LA diameter showing a trend toward significance (p=0.058) (Figure). ESUS patients had LA diameter, LAVI, MV E and MV Peak A that were more similar to ODC than CE patients.

Conclusions: LA structural and functional parameters among CE patients in our cohort were significantly different from those of ESUS and ODC patients, suggesting that ESUS patients may have lower risk of AF (and therefore lower likelihood of benefit from preemptive anticoagulation). Our study suggests that ESUS patients may benefit from long-term cardiac monitoring prior to initiation of anticoagulation therapy.

Abstract TP414: Are Periodic Limb Movements and Obstructive Sleep Apnea Associated with Atrial Fibrillation or Resistant Hypertension in Stroke and TIA Patients?

Introduction: Periodic limb movements (PLMs) and obstructive sleep apnea (OSA) have been associated with an increased risk of cardiovascular disease. There are limited data on the frequency of PLMs and OSA among a diverse cohort of stroke patients and their association with resistant hypertension and atrial fibrillation (AF).

Hypothesis: Stroke and TIA patients with PLMs or moderate-severe OSA are more likely to have resistant hypertension and AF than patients without these findings on diagnostic polysomnography (PSG).

Methods: Consecutive stroke and TIA patients referred by a vascular neurologist for PSG from October 1, 2012 to September 30, 2015 were included in this analysis. Baseline clinical characteristics and PSG results were collected retrospectively. The frequency of PLMs (mild ≥5/hour, severe ≥15/hour), arousals due to PLMs (≥5/hour), and moderate-severe OSA (Apnea-Hypopnea Index≥15) was evaluated by PSG to determine their association with AF and resistant hypertension, defined as patients whose blood pressure was not at goal with 3 antihypertensive agents of different classes or controlled with 4 or more medications.

Results: Of 103 patients (mean age 60±15 years, 50% female, 61% non-white, 76% ischemic stroke, 23% resistant hypertension) who underwent PSG (median time from cerebrovascular event to PSG 5 months), 48% had mild PLMs, 28% had severe PLMs, 14% had frequent PLM arousals and 22% had moderate-severe OSA. In multivariable analyses, non-white race was associated with lower likelihood of mild (OR 0.32, 95% CI 0.13 to 0.80) and severe PLMs (OR 0.29, 95% 0.10 to 0.79) and female sex was associated with lower likelihood of frequent PLM arousals (OR 0.38, 95% CI 0.14 to 1.00). Factors associated with moderate-severe OSA included older age (OR 1.06, 95% CI 1.016 to 1.106) and the presence of AF (OR 4.26, 95% CI 1.17 to 15.44). There was no significant association between PLMs, PLM arousals or moderate-severe OSA with resistant hypertension.

Conclusions: A significant number of stroke and TIA patients have PLMs and moderate-severe OSA. Stroke and TIA patients with AF are more likely to have moderate-severe OSA and should be referred for PSG. The presence of resistant hypertension was not associated with PLMs or moderate-severe OSA in our study.

Clopidogrel plus Aspirin for Symptomatic Intracranial Atherosclerotic Stenosis: A Pilot Study

BACKGROUND AND PURPOSE

There are limited data on the optimal duration of dual antiplatelet therapy for secondary stroke prevention in patients with symptomatic intracranial atherosclerotic disease.

METHODS

Consecutive patients presenting with high-grade (70-99%) symptomatic intracranial stenosis from January 1, 2011, to December 31, 2013, and evaluated within 30 days of the index event were eligible for this analysis. All patients underwent treatment with aspirin plus clopidogrel for a target duration of 12 months along with aggressive medical management based on the Stenting and Aggressive Medical Management for Preventing Recurrent Stroke in Intracranial Stenosis (SAMMPRIS) protocol; all patients were given gastrointestinal prophylaxis for the duration of their aspirin and clopidogrel treatment. Clinical and safety outcomes of our cohort were compared with the medical arm of the SAMMPRIS trial cohort (n = 227).

RESULTS

Our cohort included 25 patients that met the inclusion criteria. Achievement of blood pressure and LDL cholesterol targets were similar between our cohort and the SAMMPRIS cohort. At 1 year, the rates of stroke, myocardial infarction or vascular death were 0% in our cohort and 16% in the SAMMPRIS cohort (p = 0.03). At 1 year, major bleeding rates were similar between our cohort and the SAMMPRIS cohort (4 vs. 2.2%, p = 1.0).

CONCLUSION

A prolonged course of dual antiplatelet therapy for symptomatic intracranial atherosclerotic disease may be associated with less vascular events with no increase in hemorrhagic complications.

Automated CT Perfusion Ischemic Core Volume and Noncontrast CT ASPECTS (Alberta Stroke Program Early CT Score)

Background and Purpose—

The semiquantitative noncontrast CT Alberta Stroke Program Early CT Score (ASPECTS) and RAPID automated computed tomography (CT) perfusion (CTP) ischemic core volumetric measurements have been used to quantify infarct extent. We aim to determine the correlation between ASPECTS and CTP ischemic core, evaluate the variability of core volumes within ASPECTS strata, and assess the strength of their association with clinical outcomes.

Methods—

Review of a prospective, single-center database of consecutive thrombectomies of middle cerebral or intracranial internal carotid artery occlusions with pretreatment CTP between September 2010 and September 2015. CTP was processed with RAPID software to identify ischemic core (relative cerebral blood flow<30% of normal tissue).

Results—

Three hundred and thirty-two patients fulfilled inclusion criteria. Median age was 66 years (55–75), median ASPECTS was 8 (7–9), whereas median CTP ischemic core was 11 cc (2–27). Median time from last normal to groin puncture was 5.8 hours (3.9–8.8), and 90-day modified Rankin scale score 0 to 2 was observed in 54%. The correlation between CTP ischemic core and ASPECTS was fair ( R =−0.36; P <0.01). Twenty-six patients (8%) had ASPECTS <6 and CTP core ≤50 cc (37% had modified Rankin scale score 0–2, whereas 29% were deceased at 90 days). Conversely, 27 patients (8%) had CTP core >50 cc and ASPECTS ≥6 (29% had modified Rankin scale 0–2, whereas 21% were deceased at 90 days). Moderate correlations between ASPECTS and final infarct volume ( R =−0.42; P <0.01) and between CTP ischemic core and final infarct volume ( R =0.50; P <0.01) were observed; coefficients were not significantly influenced by the time from stroke onset to presentation. Multivariable regression indicated ASPECTS ≥6 (odds ratio 4.10; 95% confidence interval, 1.47–11.46; P =0.01) and CTP core ≤50 cc (odds ratio 3.86; 95% confidence interval, 1.22–12.15; P =0.02) independently and comparably predictive of good outcome.

Conclusions—

There is wide variability of CTP-derived core volumes within ASPECTS strata. Patient selection may be affected by the imaging selection method.

Internal Carotid Artery S-Shaped Curve as a Marker of Fibromuscular Dysplasia in Dissection-Related Acute Ischemic Stroke

BACKGROUND AND PURPOSE

Craniocervical fibromuscular dysplasia (FMD) is associated with dissections and with S-shaped curves in the internal carotid artery (ICA). We evaluated the occurrence of S-curves in patients presenting with acute strokes due to ICA steno-occlusive dissections.

METHODS

This was a retrospective review of the interventional databases of two academic tertiary-care institutions. The presence of ICA S-shaped curves, C-shaped curves, 360-degree loops, as well as classic FMD and atherosclerotic changes at the ICA bulb and curve/loop was determined. Cases of carotid dissections were compared with a control group (consecutive non-tandem anterior circulation strokes).

RESULTS

Twenty-four patients with carotid dissections were compared to 92 controls. Baseline characteristics and procedural variables were similar, with the exception of younger age, less frequent history of hypertension, diabetes, atrial fibrillation and stent retriever use in patients with dissections. The rates of mTICI2b-3 reperfusion, parenchymal hematoma, good outcome and mortality were similar amongst groups. The frequency of S-curves (any side without superimposed atherosclerosis) was 29% in the dissection group versus 7% in controls (p < 0.01). S-curves were typically mirror images within the dissection group (85% had bilateral occurrence). The frequency of C-shaped and 360-degree curves was similar between groups. FMD changes within the craniocervical arteries were statistically more common in dissection patients. Ten patients (41%) of the dissection group had S-curves or classic FMD changes. Multivariate analysis indicated that S-curves were independently associated with the presence of dissections.

CONCLUSION

S-shaped ICA curves are predictably bilateral, highly associated with carotid dissections in patients with moderate to severe strokes, and may suggest an underlying presence of FMD.

Early Endovascular Treatment in Intravenous Tissue Plasminogen Activator–Ineligible Patients

Background and Purpose—

Intravenous tissue-type plasminogen activator (tPA) treatment in acute stroke has many exclusion criteria. We aimed to assess the safety and efficacy of endovascular therapy (ET) in intravenous (IV) tPA-ineligible patients.

Methods—

Retrospective analysis of a prospectively collected database of consecutive patients treated with ET within 6 hours of stroke onset between September 2010 and April 2015. Patients treated with IV-tPA followed by ET were compared with those treated with ET alone because of IV-tPA ineligibility. Efficacy and safety end points included the rates of good outcome (90-day modified Rankin scale score ≤2), successful reperfusion (modified Treatment in Cerebral Ischemia 2b-3), parenchymal hematoma (PH-1 and PH-2), and 90-day mortality. Univariate and logistic regression were performed to identify the predictors of outcomes.

Results—

A total of 422 patients were included. Two hundred and fifty-three (59%) patients received IV-tPA+ET, and 169 (41%), ET alone. Combined IV-tPA+ET patients were slightly younger (64.9±15.2 versus 67.9±14.9 years; P =0.05), more often males (56% versus 44%; P =0.01), and had less hypertension (70% versus 81%; P =0.02) and vertebrobasilar occlusions (3% versus 8%; P =0.02). The remaining baseline characteristics, including National Institutes of Health Stroke Scale score (20 [15–23] versus 19 [15–24]; P =0.85), Alberta Stroke Program Early CT Score (ASPECTS; 8 [7–9] versus 8 [7–9]; P =0.24), and stroke onset to puncture times (235±70 versus 240±81 minutes; P =0.27), were similar across both groups. There were no significant differences in the rates of modified Treatment in Cerebral Ischemia 2b-3 (83% versus 80%; P =0.52), 90-day modified Rankin scale score ≤2 (45% versus 38%; P =0.21), or any PH (3% versus 5%; P =0.21). Unadjusted 90-day mortality was higher with ET alone (21% versus 34%; P <0.01); however, IV-tPA ineligibility was not associated with modified Treatment in Cerebral Ischemia 2b-3, any PH, good outcome, or 90-day mortality on logistic regression.

Conclusions—

IV-tPA-eligible and -ineligible patients seem to have similar outcomes after early ET.

Abstract TP27: Endovascular Treatment Within 6 Hours is Safe and Benefitial in IV-tPA Ineligible Patients

Background: Treatment with IV tPA in acute stroke has restricted applicability due to its many contraindications. Indeed, the recent AHA guidelines provide only limited support to endovascular therapy (ET) in non IV-tPA patients as only few of these patients were included in the recent randomized ET trials. Our study aims to access the safety and efficacy of ET within 6 hours of stroke onset in patients ineligible to IV-tPA.

Methods: Retrospective analysis of a prospectively collected ET database between September/2010-April/2015 for patients presenting within 6 hours of symptom onset. Patients who underwent ET alone due to IV-tPA ineligibility were compared to those who underwent IV-tPA + ET. Primary and secondary efficacy outcome included the rates of good outcome (90-day mRS 0-2) and successful reperfusion (mTICI 2b-3), respectively. Safety outcome was accessed by rates of any parenchymal hematoma (PH-1 and PH-2) and 90-day mortality.

Results: 422 patients were included in the analysis, 253 received combined IV-tPA + ET (59% overall cohort) and 169 were treated with ET alone (41%). Patients in the ET alone group were slightly older (65±16 vs. 68±15 years-old, p=0.05) and more frequently had basilar occlusions (3% vs. 8%, p=0.02) but the remaining baseline characteristics were otherwise well balanced including NIHSS (19±5 vs. 18±6, p=0.85), ASPECTS (7.7±1.6 vs. 7.9±1.5, p=0.24), time stroke onset to puncture (235±70 vs. 240±81 min, p=0.27), and glucose levels (135±50 vs. 143±60 mg/dL, p=0.13). There were no differences in the rates of 90-day mRS≤2 (45% vs. 38%, p=0.21), mTICI 2b-3 (83% vs. 80%, p=0.52), or any PH (3% vs. 5%, p=0.21) across the combined therapy and ET alone groups. The 90-day mortality was higher in patients in the ET alone (e.g. IV t-PA ineligible) patients (21% vs. 34%, p<0.01). However, after multivariate analysis adjustments the use of IV-tPA was not associated with any significant differences in the rates of good outcome, successful reperfusion, any PH, or 90-day mortality.

Conclusion: Our data supports aggressive treatment with ET in IV tPA ineligible patients within 6 hours of stroke onset as these patients appear to have similar outcomes to IV tPA eligible patients and are known to have a poor natural history in the absence of reperfusion.

Abstract 156: Poor Correlation Between Non-contrast CT (NCCT) Aspects and CT Perfusion (CTP)-derived Ischemic Core Volumes

Introduction and Objectives: The best imaging method for selecting patients for thrombectomy remains unknown. We aim to evaluate the correlation between ASPECTS and RAPID automated CT perfusion (CTP) ischemic core volumes.

Methods: This was a retrospective review of a prospectively collected interventional database. We included patients from January 2011-February 2015 with MCA-M1, MCA-M2 or ICA-terminus occlusions that underwent good quality RAPID CTP. The correlation between ASPECTS and CTP-derived ischemic core volumes (CBF<30% contralateral hemisphere) was analyzed.

Results: A total of 188 were included. Mean age was 62.4±14.8, 51% were males, 71% had hypertension, 34% dyslipidemia, 33% atrial fibrillation, 21% diabetes, and 37% received IV-tPA. Mean baseline NIHSS was 17.1±5.4 and ASPECTS 7.7±1.5. Time from last-known-normal to groin puncture was 6.9±4.3 hours. Sixty-one percent had MCA-M1, 21% MCA-M2, and 18% ICA-terminus occlusions. Seventy-two percent were treated with stent-retrievers, leading to 82% mTICI 2b-3 reperfusion, 9% parenchymal hemorrhages, 54% mRS0-2 and 11% mortality at 90 days. The correlation between ASPECTS and CTP-derived ischemic core was weak (rho 0.27; p<0.01). The attached figure demonstrates the very wide variability of ischemic core volumes across specific ASPECTS.

Conclusion: There is wide variability of CTP-derived ischemic core volumes within specific ASPECTS. Patient selection may significantly be affected by the imaging selection method.

Abstract WMP67: Stroke Screening Tools Have High Specificity for Detecting Large Vessel Occlusion in a Southeastern US Prospective Cohort Study

Introduction: Previously reported stroke screening tools used to identify large vessel occlusion (LVO) have been developed based on retrospective analyses or cohorts enrolled in a clinical trial.

Hypothesis: Stroke screening tools may have lower specificity for detection of LVO when tested in a prospective cohort study of patients identified by emergency medical services (EMS) to have stroke signs and symptoms.

Methods: Consecutive patients presenting to a stroke center with stroke symptoms or a positive FAST screen by EMS within 6 hours from stroke onset or wakeup were included in this prospective analysis. All patients were initially evaluated by a neurology attending or resident and underwent non-contrast CT (NCCT). Patients identified to have a stroke mimic on initial assessment or hemorrhagic stroke on NCCT did not undergo intracranial large artery imaging (iLAI); all remaining patients underwent iLAI. Sensitivity and specificity for LVO with the following screens were assessed: NIHSS ≥ 15, LAMS ≥ 4, RACE ≥ 5 and CPSSS ≥2.

Results: Of 92 patients (mean age 69±17 years, mean NIHSS 8) evaluated over the 3 month study period, 41 (45%) were identified to have a stroke mimic and 9 (10%) had a hemorrhagic stroke on NCCT; 19 (21%) patients had LVO. The remaining 42 patients underwent iLAI within <24 hrs (median time from last seen normal time to imaging 215 minutes). Sensitivity and specificity for NIHSS, LAMS, RACE and CPSSS scales to detect LVO are shown in the Table; there was relatively high specificity among all scales which improved after excluding patients with stroke mimics and hemorrhagic stroke on NCCT.

Conclusion: Previously published stroke screening tools have high specificity for detection of LVO when tested in a prospective cohort study of patients identified by EMS to have stroke signs and symptoms.

Abstract TP18: S-shaped Internal Carotid Artery Curve in Dissection-related Acute Ischemic Stroke

Background and Purpose: Craniocervical fibromuscular dysplasia (FMD) has been associated with dissections. Recently, the presence of an S-shaped curve in the ICA has been described as a marker of FMD. We evaluated the occurrence of S-shaped curves in acute ischemic stroke (AIS) patients presenting with ICA steno-occlusive dissections.

Methods: This was a retrospective review of the interventional database of two academic tertiary care institutions. Cases of carotid dissections were compared with a control group (consecutive non-tandem anterior circulation strokes). The presence of ICA S-shaped curves, C-shaped curves, 360° loops, as well as, FMD changes and atherosclerotic changes at the ICA bulb and curve/loop was determined by evaluation of conventional-angiogram and CTA.

Results: Twenty-four patients with carotid dissections were identified and compared to 92 controls. The baseline characteristics were similar, with the exception of expected younger age and less prevalent history of hypertension, diabetes and atrial fibrillation in the dissection group. Procedural variables were also similar, with the exception of a large percentage of the use of stentretrievers in the control group. The occurrence of parenchymal hemorrhages, good outcomes and mortality were similar amongst the two groups. The frequency of S-shaped curves on either side was 29% in the dissection group vs. 7% in the control group (p<0.01). The S-shaped ICA curves were typically mirror images within the dissection group (85% of the patients with an S-shaped curves had bilaterally occurrence). The frequency of C-shaped and 360 degree curves was statistically similar between groups. FMD changes within the craniocervical arteries were statistically more common in the patients with dissections. Ten patients of the dissection group had either FMD changes or an S-Shaped curve (41%). Multivariate analysis indicated that S-shaped curves were independently associated with the presence of dissections.

Conclusion: S-shaped ICA curves are predictably bilateral, independently associated with carotid dissections in patients undergoing thrombectomy for acute ischemic stroke, and may indicate the underlying presence of FMD.

Large Volumes of Critically Hypoperfused Penumbral Tissue Do Not Preclude Good Outcomes After Complete Endovascular Reperfusion

Background and Purpose—

Acute ischemic stroke patients with large volumes of severe hypoperfusion ( T max >10 s>100 mL) on magnetic resonance imaging have a higher likelihood of intracranial hemorrhage and poor outcomes after reperfusion. We aim to evaluate the impact of the extent of T max >10 s CTP lesions in patients undergoing successful treatment.

Methods—

Retrospective database review of endovascular acute ischemic stroke treatment between September 2010 and March 2015 for patients with anterior circulation occlusions with baseline RAPID CTP and full reperfusion (mTICI 3). The primary outcome was the impact of the T max >10 s lesion spectrum on infarct growth. Secondary safety and efficacy outcomes included parenchymal hematomas and good clinical outcomes (90-day modified Rankin Scale score, 0–2).

Results—

Of 684 treated patients, 113 patients fit the inclusion criteria. T max >10 s>100 mL patients (n=37) had significantly higher baseline National Institutes of Health Stroke Scale (20.7±3.8 versus 17.0±5.9; P <0.01), more internal carotid artery terminus occlusions (29% versus 9%; P =0.02), and larger baseline (38.6±29.6 versus 11.7±15.8 mL; P <0.01) and final (60.7±60.0 versus 29.4±33.9 mL; P <0.01) infarct volumes when compared with patients without T max >10 s>100 mL (n=76); however, the 2 groups were otherwise well balanced. There were no significant differences in infarct growth (22.1±51.6 versus 17.8±32.4 mL; P =0.78), severe intracranial hemorrhage (PH2: 2% versus 4%; P =0.73), good outcomes (90-day mRS score, 0–2: 56% versus 59%; P =0.83), or 90-day mortality (16% versus 7%; P =0.28). On multivariate analysis, only baseline National Institutes of Health Stroke Scale (odds ratio, 1.19; 95% confidence interval, 1.06–1.34; P <0.01) and baseline infarct core volume (odds ratio, 1.05; 95% confidence interval, 1.02–1.08; P <0.01) were independently associated with T max >10 s>100 mL. There was no association between T max >10 s>100 mL with any PH, good outcome, or infarct growth.

Conclusions—

In the setting of limited baseline ischemic cores, large T max >10 s lesions on computed tomographic perfusion do not seem to be associated with a higher risk of parenchymal hematomas and do not preclude good outcomes in patients undergoing endovascular reperfusion with contemporary technology.

Endovascular Treatment for Acute Ischemic Stroke in the Setting of Anticoagulation

Background and Purpose—

Oral anticoagulation (OAC) plays a major role in atrial fibrillation stroke prevention but represents a contraindication to intravenous tissue-type plasminogen activator. Intra-arterial therapy remains a potential reperfusion strategy in these patients; however, supporting data are scarce.

Methods—

Retrospective analysis of prospectively collected consecutive intra-arterial therapies from October 2010 to March 2015 comparing OAC (vitamin-K antagonists and novel oral anticoagulants) versus normal hemostasis versus intravenous tissue-type plasminogen activator patients. Primary safety end point is parenchymal hematoma. Secondary safety end point is 90-day mortality. Efficacy end points are successful reperfusion (modified Thrombolysis in Cerebral Infarction, 2b-3) and good outcome (90-day modified Rankin Scale score of 0–2). Logistic regression for predictors of parenchymal hematoma was performed.

Results—

A total of 604 patients were qualified for the study. Baseline and outcomes variables were overall similar for vitamin-K antagonists (n=29) and novel oral anticoagulants (n=17) patients. When compared with normal hemostasis (n=265) and intravenous tissue-type plasminogen activator (n=297), OAC (n=46) patients were older and had more comorbidities. There were no statistically significant differences in the rates of parenchymal hematoma (8% versus 5%; P =0.42), 90-day modified Rankin Scale score of 0 to 2 (30% versus 40%; P =0.26), and 90-day mortality (32% versus 26%; P =0.46) among OAC and normal hemostasis patients. Similarly, there were no significant differences between OAC and intravenous tissue-type plasminogen activator patients in terms of parenchymal hematoma (8% versus 4%; P =0.16), 90-day modified Rankin Scale score of 0 to 2 (30% versus 43%; P =0.13), and 90-day mortality (32% versus 22%; P =0.18). The use of OAC was not associated with the occurrence of parenchymal hematoma on multivariate logistic regression analysis.

Conclusions—

Intra-arterial therapy seems to be safe in patients taking OACs; however, our study showed a nonsignificant increase in hemorrhage and mortality with a nonsignificant decrease in good outcomes in comparison with non-OAC patients. Although these nominal differences may have been related to older age and more comorbidities in the OAC group, larger studies are needed to confirm our findings given our limited sample size.

The negative impact of spasticity on the health-related quality of life of stroke survivors: a longitudinal cohort study

Background

Spasticity often leads to symptomatic and functional problems that can cause disability for stroke survivors. We studied whether spasticity has a negative impact on health-related quality of life (HRQoL).

Methods

As part of the Greater Cincinnati/Northern Kentucky Stroke Study (NCT00642213), 460 ischemic stroke patients were interviewed during hospitalization and then followed over time. HRQoL was measured by the Physical Component Summary (PCS) and Mental Component Summary (MCS) scores of the Short Form-12 (SF-12), EuroQol-5 dimension (EQ-5D), and Stroke-Specific Quality of Life (SSQOL) instruments, with lower scores indicating worse health. HRQoL differences between stroke survivors with and without spasticity were compared, adjusting for age, race, stroke severity, pre-stroke function, and comorbidities.

Results

Of the 460 ischemic stroke patients, 328 had spasticity data available 3 months after their stroke (mean age of 66 years, 49 % were female, and 26 % were black). Of these patients, 54 (16 %) reported having spasticity. Three months following their stroke, patients who reported spasticity had lower mean scores on the PCS (29.6 ± 1.4 vs 37.3 ± 0.6; P < .001), EQ-5D (0.59 ± 0.03 vs 0.71 ± 0.01; P < .001), and SSQOL (3.57 ± 0.08 versus 3.78 ± 0.03; P = .03) compared with patients who did not report spasticity. Lower HRQoL scores were also observed at the 1-year (PCS, EQ-5D, and SSQOL) and 2-year (EQ-5D and SSQOL) interviews in those with spasticity compared with those without spasticity.

Conclusions

Statistically and clinically meaningful differences in HRQoL exist between stroke survivors with and without spasticity.

Sulcal effacement with preserved gray-white junction: a sign of reversible ischemia

BACKGROUND AND PURPOSE

Sulcal effacement with preserved underlying gray-white matter junction (isolated sulcal effacement [ISE]) in acute ischemic stroke may not represent irreversible parenchymal injury. We aimed to evaluate the frequency and significance of ISE in patients with large vessel occlusion acute ischemic stroke.

METHODS

Consecutive acute ischemic stroke patients with middle cerebral artery M1 or internal carotid artery terminus occlusions who underwent computed tomography angiogram/perfusion followed by intra-arterial therapy were screened for ISE.

RESULTS

Out of the 568 patients who underwent intra-arterial therapy between March 2011 and September 2014, 108 fulfilled inclusion criteria. ISE was present in 8 (7.4%) patients (age 55.7±10.5 years, 6 female, baseline National Institutes of Health Stroke Scale 16.1±3.8, 5 middle cerebral artery-M1, and 3 internal carotid artery terminus occlusions). Computed tomography angiogram revealed engorged/dilated leptomeningeal vessels obliterating the sulci within the areas of effacement, whereas computed tomography perfusion indicated normal-to-increased cerebral blood volume and prolonged Tmax in all patients. Modified treatment in cerebral ischemia (mTICI) 2b-3 reperfusion was achieved in all patients. Follow-up imaging confirmed no infarct in the ISE area in all patients, and 5 (62%) had modified Rankin Scale 0 to 2 at 3 months.

CONCLUSIONS

Sulcal effacement with preserved gray-white delineation is occasionally visualized in patients with proximal occlusion strokes, relates to robust leptomeningeal collaterals, and indicates preserved underlying parenchyma. ISE should not be used to exclude patients from thrombectomy.

Abstract T P24: Neurointervention for Acute Ischemic Stroke Caused by Carotid Dissection

Introduction: Data related to the treatment of patients with acute ischemic stroke caused by carotid artery dissection is scarce. Methods: We retrospectively reviewed our interventional stroke database Sep 2010 - Jan 2014 to investigate the clinical and radiological characteristics of patients presenting with tandem cervical and intracranial occlusions due to cervical carotid dissection. Results: Out of 504 consecutive patients treated with endovascular therapy for acute ischemic stroke during the study period, 12 (2.5%) patients were observed to have cervical carotid artery dissection as the underlying etiology. Mean age was 56±13 years, 75% were male, 50% received IV t-PA, mean NIHSS was 20±5, 75% had CT ASPECTS≥7, and mean time from last known normal to groin puncture was 6±3 hours. There were 4 MCA M1, 1 MCA M2 and 7 ICA-T occlusions. Extracranial carotid stent was used in 58% and angioplasty in 8% of cases. In 33% of the cases, the carotid dissection was not stented due to the fear of hemorrhagic transformation in cases of IV thrombolysis (presumably increased risk if dual antithrombotics used). IA tPA was used in 41% of cases, while Merci in 16%, Penumbra in 58%, and stentretrivers in 50%. Intracranial TICI 2b-3 reperfusion was achieved in 91% of patients, with PH2 hemorrhage in 8% and mRS at 90 days in 45% of cases. Conclusions: Carotid dissections with associated intracranial occlusions are often refractory to IV tPA and present with a high stroke severity. These lesions are amenable to endovascular therapy resulting in high rates of reperfusion with an acceptable safety profile.

Abstract W MP100: Applying Real-Time Location Systems to Acute Stroke Workflow: A Novel Quality Improvement Tool

Background: Real-Time Location Systems (RTLS) utilize tracking tags and detectors to locate objects or people. This technology has been implemented in healthcare, chiefly to track hospital assets, and a few healthcare systems have applied this technology to track patients in the emergency department. This pilot study tested the feasibility of RTLS to monitor the acute stroke workflow in a large, urban hospital.

Methods: An asset tracking RTLS was installed in a large, urban hospital. A series of 21 acute stroke patients were tracked throughout the workflow process by a human observer and via RTLS asset tag attached to the patient’s hospital equipment. A Wi-Fi detector documented initial patient arrival times in the ER Hallway, radiofrequency/infrared (RFID/IR) detectors documented ER CT scanner and ER patient room times. Patient Arrival and departure times in the emergency room (ER) and radiology CT scanner were measured. Time differences between human observer and RTLS were calculated.

Results: A total of 21 patients were tracked with RTLS. The mean time difference, interquartile range and standard deviation in minutes are as follows: initial arrival (mean 106, IQR 112, SD 197); CT arrival ( mean 1, IQR 1, SD 0.86); CT departure (mean 2, IQR 2, SD 1.13); patient return to ED (mean 1, IQR 1, SD 0.94).

Discussion: Our data demonstrate that RTLS can provide accurate, real-time patient location information, and has the potential to provide data for quality improvement. Combination RFID/IR detectors provided accurate time information while the Wi-Fi detector, proved unreliable for initial arrival times. Our preliminary data supports the development of an unique RTLS system specifically designed to allow for complete visualization of the stroke workflow from patient arrival to treatment along with a dashboard user interface to facilitate treatment team coordination.

Abstract T P292: Utility of Depression and Cognitive Impairment Screening during Hospitalization for Acute Stroke

Background: Comprehensive stroke center standards currently require that stroke patients are assessed for cognitive impairment and depression prior to discharge. There is limited data on the utility of cognitive and depression screening within the first week after a stroke.

Methods: We retrospectively identified patients discharged with a primary diagnosis of stroke [ischemic stroke (IS), intracerebral hemorrhage (ICH), subarachnoid hemorrhage (SAH)] from January 1 to August 31, 2013 at Emory University Hospital. The Patient Health Questionnaire 2 (PHQ-2) was administered to screen for depression with a score of ≥ 3 considered a positive depression screen. The 6-item screener was administered to screen for cognitive impairment with a score of ≤ 4 considered a positive cognitive impairment screen. Reliability of the screens was determined by comparing results of inpatient and follow-up screens performed 7-14 days after discharge in a subgroup of patients.

Results: Of 315 patients (mean age 61 years, 57% female), 43% had IS (mean NIHSS 8), 31% had SAH (mean Hunt/Hess score 2), and 26% had ICH (mean ICH score 2). Screens were completed (mean 4 days) in 183 (58%) patients, including 64% of IS, 55% of SAH and 46% of ICH patients (IS vs ICH, p=0.01); intubation (32%), delirium (23%), and aphasia (17%) were the most common reasons for inability to complete a screen. A positive depression screen was seen in 22% and a positive cognitive screen in 26% of patients. In age and risk adjusted analysis, history of prior stroke was associated with a positive depression screen (OR 3.39, p=0.01). Having a SAH was a significant predictor of a positive cognitive impairment screen (OR 2.74, p=0.04) while being female was associated with a lower odds of a positive cognitive impairment screen (OR 0.36, p=0.01). Among a random subgroup of 36 patients, reliability of the inpatient screening results was low when compared to screening results after discharge.

Conclusions: More than 40% of stroke patients were unable to complete their inpatient depression and cognitive screens due to acute medical illness. Further study is needed to evaluate the reliability of these screening test results when administered before discharge.